Comparative Pharmacology
Head-to-head clinical analysis: MICRODERM versus RENOVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICRODERM versus RENOVA.
MICRODERM vs RENOVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MICRODERM is a brand name for tretinoin, a retinoid that binds to retinoic acid receptors (RARα, RARβ, RARγ) and retinoid X receptors (RXR), modulating gene transcription to promote keratinocyte differentiation, reduce proliferation, and normalize desquamation, thereby decreasing comedone formation and inflammation.
Renova (tretinoin) is a retinoid that binds to retinoic acid receptors (RARα, RARβ, RARγ) and retinoid X receptors (RXRα, RXRβ, RXRγ). It modulates gene expression, increasing collagen synthesis, reducing collagen breakdown via inhibition of matrix metalloproteinases, and promoting epidermal cell turnover and proliferation.
MICRODERM is not a recognized pharmaceutical agent; no standard dosing information available.
Apply a thin layer to affected area once daily at bedtime. Use only fingertips to apply (0.1% cream).
None Documented
None Documented
Terminal elimination half-life is 12 hours (range 10-15 h); requires dose adjustment in renal impairment when CrCl <30 mL/min.
Terminal half-life is 2-4 hours in patients with normal renal function; prolonged to 18-24 hours in end-stage renal disease
Renal excretion accounts for 70% as unchanged drug, biliary/fecal elimination 20%, hepatic metabolism 10%.
Renal (approximately 99% as unchanged drug), biliary/fecal (<1%)
Category C
Category C
Topical Retinoid
Topical Retinoid